NCT00573950

Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness

Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Korea University Anam Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Cilostazol is an antiplatelet agent used to reduce the symptoms of intermittent claudication. Cilostazol inhibits phosphodiesterase III (PDE III), which causes it to be a vasodilator and inhibitor of platelet aggregation. Recently there were report of beneficial effect of cilostazol like vasodilation, lipid metabolism, and cytokine production. But there were few clinical studies that support these effects of cilostazol. The purpose of this study is to evaluate the vasodilatory and anti-inflammatory effect of cilostazol presented by PWV and plasma adipocytokines.

Conditions

• Diabetes Mellitus, Type 2
• Metabolic Syndrome X

Interventions

Type	Name	Description
DRUG	cilostazol	50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
DRUG	Placebo	Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks

Timeline

• Start date: 2007-12-01
• Completion: 2008-12-01
• First posted: 2007-12-14
• Last updated: 2007-12-14

Locations

1 site across 1 country: South Korea